ERS International Congress 2023: highlights from the Thoracic Oncology Assembly.

Autor:	Catarata MJ; Pulmonology Department, Hospital de Braga, Braga, Portugal.; Tumour and Microenvironment Interactions Group, I3S - Institute for Health Research and Innovation, University of Porto, Porto, Portugal., Creamer AW; Great Western Hospitals NHS Foundation Trust, Swindon, UK., Dias M; Pulmonology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal., Toland S; Department of Medicine, Letterkenny University Hospital, Letterkenny, Ireland., Chaabouni M; Asklepios Klinik Altona, Department of Internal Medicine II, Pulmonology and Thoracic Oncology Section, Hamburg, Germany., Verbeke K; Department of Respiratory Medicine, University Hospital Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium., Vieira Naia J; Pulmonology Department, Hospital de Braga, Braga, Portugal., Hassan M; Chest Diseases Department, Alexandria University Faculty of Medicine, Alexandria, Egypt., Naidu SB; Department of Respiratory Medicine, University College London, London, UK., Lynch GA; Academic Respiratory Unit, University of Bristol Medical School, Bristol, UK., Blyth KG; Queen Elizabeth University Hospital, Glasgow, UK.; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK., Rahman NM; Oxford University Hospitals NHS Foundation Trust, Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Headington, UK., Hardavella G; 9th Department of Respiratory Medicine, Sotiria Athens Chest Diseases Hospital, Athens, Greece.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2024 Feb 26; Vol. 10 (1). Date of Electronic Publication: 2024 Feb 26 (Print Publication: 2024).
DOI:	10.1183/23120541.00860-2023
Abstrakt:	Lung cancer is the leading cause of cancer mortality in the world. It greatly affects the patients' quality of life, and is thus a challenge for the daily practice in respiratory medicine. Advances in the genetic knowledge of thoracic tumours' mutational landscape, and the development of targeted therapies and immune checkpoint inhibitors, have led to a paradigm shift in the treatment of lung cancer and pleural mesothelioma. During the 2023 European Respiratory Society Congress in Milan, Italy, experts from all over the world presented their high-quality research and reviewed best clinical practices. Lung cancer screening, management of early stages of lung cancer, application of artificial intelligence and biomarkers were discussed and they will be summarised here. Competing Interests: Conflict of interest: The authors have nothing to disclose. (Copyright ©The authors 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu